American Family Children's Hospital
Vincent L. Cryns, MD close
Vincent L. Cryns, MD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Vincent L. Cryns, MD Print Friendly Page

Dr. Cryns is Chief of the Division of Endocrinology, Diabetes and Metabolism. His major clinical interests are osteoporosis, general endocrinology and metabolic disorders.


Endocrinology, Diabetes and Metabolism

UW Health Clinics

West Clinic
(608) 263-5010 | (800) 323-8942 | Map
West Clinic
(608) 263-5010 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Endocrinology, Diabetes & Metabolism
Fellowship Massachusetts General Hospital, Boston, MA, MA
Residency Dartmouth Hitchcock Medical Center, Lebanon, NH
Internship Massachusetts General Hospital, Boston, MA, MA
Medical School Harvard Medical School, Boston, MA, 1987


Best Doctors® in America 2014

Best Doctors in America® 2013

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Programs & Conditions


Dr. Cryns' research focuses on understanding how cells die. He leads a team of scientists who are interested in understanding how abnormalities in cell death contribute to cancer and obesity and in translating these insights into improved therapies. Dr. Cryns' research is funded by the NIH, the Breast Cancer Research Foundation, and other agencies. His work has been featured on National Public Radio's "All Things Considered" and highlighted in Nature and Nature Reviews Cancer. Dr. Cryns has been the recipient of several awards, including an Outstanding Junior Faculty Award from the Avon Foundation, and he is an elected member of the American Society for Clinical Investigation.

PubMed Articles
Strekalova E Malin D Rajanala H Cryns VL . Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression. Breast Cancer Res Treat. 2017 Jun;163(3):435-447
[PubMed ID: 28324269]
Ugolkov A Gaisina I Zhang JS Billadeau DD White K Kozikowski A Jain S Cristofanilli M Giles F O'Halloran T Cryns VL Mazar AP . GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016 Oct 1;380(2):384-92
[PubMed ID: 27424289]
Toft DJ Fuller M Schipma M Chen F Cryns VL Layden BT . αB-crystallin and HspB2 deficiency is protective from diet-induced glucose intolerance. Genom Data. 2016 Sep;9:10-7
[PubMed ID: 27330996]
Malin D Petrovic V Strekalova E Sharma B Cryns VL . αB-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target. Pharmacol Ther. 2016 Apr;160:1-10
[PubMed ID: 26820756]
Malin D Strekalova E Petrovic V Rajanala H Sharma B Ugolkov A Gradishar WJ Cryns VL . ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo. Oncogene. 2015 Nov 5;34(45):5626-34
[PubMed ID: 25684139]
Voduc KD Nielsen TO Perou CM Harrell JC Fan C Kennecke H Minn AJ Cryns VL Cheang MCU . αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. NPJ Breast Cancer. 2015 Oct 21;1
[PubMed ID: 27656679]
Strekalova E Malin D Good DM Cryns VL . Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression. Clin Cancer Res. 2015 Jun 15;21(12):2780-91
[PubMed ID: 25724522]
Fernando IR Ferris DP Frasconi M Malin D Strekalova E Yilmaz MD Ambrogio MW Algaradah MM Hong MP Chen X Nassar MS Botros YY Cryns VL Stoddart JF . Esterase- and pH-responsive poly(β-amino ester)-capped mesoporous silica nanoparticles for drug delivery. Nanoscale. 2015 Apr 28;7(16):7178-83
[PubMed ID: 25820516]
Halo TL McMahon KM Angeloni NL Xu Y Wang W Chinen AB Malin D Strekalova E Cryns VL Cheng C Mirkin CA Thaxton CS . NanoFlares for the detection, isolation, and culture of live tumor cells from human blood. Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17104-9
[PubMed ID: 25404304]
Moyer TJ Finbloom JA Chen F Toft DJ Cryns VL Stupp SI . pH and amphiphilic structure direct supramolecular behavior in biofunctional assemblies. J Am Chem Soc. 2014 Oct 22;136(42):14746-52
[PubMed ID: 25310840]
Malin D Strekalova E Petrovic V Deal AM Al Ahmad A Adamo B Miller CR Ugolkov A Livasy C Fritchie K Hamilton E Blackwell K Geradts J Ewend M Carey L Shusta EV Anders CK Cryns VL . αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res. 2014 Jan 1;20(1):56-67
[PubMed ID: 24132917]
Frasconi M Liu Z Lei J Wu Y Strekalova E Malin D Ambrogio MW Chen X Botros YY Cryns VL Sauvage JP Stoddart JF . Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles. J Am Chem Soc. 2013 Aug 7;135(31):11603-13
[PubMed ID: 23815127]
Petrovic V Malin D Cryns VL . αB-crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation. Breast Cancer Res Treat. 2013 Apr;138(2):415-25
[PubMed ID: 23471649]
Goldberg MS Hook SS Wang AZ Bulte JW Patri AK Uckun FM Cryns VL Hanes J Akin D Hall JB Gharkholo N Mumper RJ . Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond). 2013 Feb;8(2):299-308
[PubMed ID: 23394158]
Toft DJ Moyer TJ Standley SM Ruff Y Ugolkov A Stupp SI Cryns VL . Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer. ACS Nano. 2012 Sep 25;6(9):7956-65
[PubMed ID: 22928955]
Soukasene S Toft DJ Moyer TJ Lu H Lee HK Standley SM Cryns VL Stupp SI . Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin. ACS Nano. 2011 Nov 22;5(11):9113-21
[PubMed ID: 22044255]
Su J Chen F Cryns VL Messersmith PB . Catechol polymers for pH-responsive, targeted drug delivery to cancer cells. J Am Chem Soc. 2011 Aug 10;133(31):11850-3
[PubMed ID: 21751810]
Malin D Chen F Schiller C Koblinski J Cryns VL . Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer. Clin Cancer Res. 2011 Aug 1;17(15):5005-15
[PubMed ID: 21653692]
Toft DJ Cryns VL . Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 2011 Feb;25(2):199-211
[PubMed ID: 20861225]
Antin JH Aplin AE Cheng SY Emmert-Buck MR Cryns VL Wang D . American journal of cancer research: editorial board (2011). Am J Cancer Res. 2011;1(6):817-22
[PubMed ID: 22016829]